Skip to main content

Systems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification

Objective

Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER+), and are treated with endocrine therapies (ET). MESI-STRAT will develop new concepts for knowledge-based stratification of patients into subgroups with different ET resistance mechanisms. We will establish predictive models for (1) patient stratification prior and during ET; (2) recurrence risk assessment when ending ET; (3) marker panel development to guide targeted therapies for ET-resistant patients; (4) novel ET resistance mechanism-based therapy design.

The unique collection of matched BC tissue, serum, and >10 years follow-up from the patient organization PATH is essential for the longitudinal analysis of ET resistance and relapse. Our team of oncologists, modelers, bioinformaticians and experimentalists will develop new computational models in combination with network analyses and pharmacogenomics, to integrate multi-omics data and explore metabolic and signaling (MESI) networks driving ET resistance. Metabolite marker panels measured in biological fluids will enable patient stratification, resistance monitoring and clinical decision-making. This is a new concept as BC metabolism is poorly explored for diagnostics and therapy. Upon successful validation in preclinical models, the predictive marker panels and related treatments will be jointly investigated by our clinical and industrial partners in clinical studies. Our 3 SMEs will closely co-develop the research, and directly exploit the MESI-STRAT results.

BC accounts for the highest cancer-related health-care costs in the EU. Our stratification concepts will increase cost effectiveness and the patients’ quality of life by (1) avoiding ineffective therapies, (2) marker detection in body fluids without surgical interventions, and (3) reducing clinical trial cohorts by improved stratification. This will accelerate the translation of MESI-STRAT results into medical use.

Call for proposal

H2020-SC1-2017-Two-Stage-RTD
See other projects for this call

Coordinator

UNIVERSITAET INNSBRUCK
Address
Innrain 52
6020 Innsbruck
Austria
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 607 913,13

Participants (16)

STIFTUNG PATIENTS TUMORBANK OF HOPE- DIE PATIENTENEIGENE TUMORGEWEBEBANK DER HOFFNUNG (PATH)
Germany
EU contribution
€ 250 550
Address
Max-hempel Street 3
86153 Augsburg
Activity type
Research Organisations
UNIVERSITATSKLINIKUM HEIDELBERG
Germany
EU contribution
€ 109 402,09
Address
Im Neuenheimer Feld 672
69120 Heidelberg
Activity type
Higher or Secondary Education Establishments
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Germany
EU contribution
€ 871 350
Address
Im Neuenheimer Feld 280
69120 Heidelberg
Activity type
Research Organisations
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Spain
EU contribution
€ 220 098,75
Address
Calle Nazaret 115-117
08035 Barcelona
Activity type
Research Organisations
DE DUVE INSTITUTE AISBL
Belgium
EU contribution
€ 289 000
Address
Avenue Hippocrate 75/50
1200 Bruxelles
Activity type
Research Organisations
UNIVERSITETET I BERGEN
Norway
EU contribution
€ 679 520
Address
Museplassen 1
5020 Bergen
Activity type
Higher or Secondary Education Establishments
UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET
Norway
EU contribution
€ 366 925
Address
Hansine Hansens Veg 14
9019 Tromso
Activity type
Higher or Secondary Education Establishments
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
EU contribution
€ 258 687,50
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
Activity type
Higher or Secondary Education Establishments
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany
EU contribution
€ 398 706,25
Address
Chariteplatz 1
10117 Berlin
Activity type
Higher or Secondary Education Establishments
UNIVERSITY OF DURHAM

Participation ended

United Kingdom
EU contribution
€ 0
Address
Stockton Road The Palatine Centre
DH1 3LE Durham
Activity type
Higher or Secondary Education Establishments
NEUROIMMUN GMBH
Germany
EU contribution
€ 131 750
Address
Unterweingartenfeld 6
76135 Karlsruhe
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SYSBIOSIM BV

Participation ended

Netherlands
EU contribution
€ 0
Address
Galileiweg 8
2333 BD Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HITS GGMBH
Germany
EU contribution
€ 224 687,50
Address
Schloss Wolfsbrunnenweg 35
69118 Heidelberg
Activity type
Research Organisations
ACADEMISCH ZIEKENHUIS GRONINGEN
Netherlands
EU contribution
€ 223 524,37
Address
Hanzeplein 1
9713 GZ Groningen
Activity type
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAT INNSBRUCK
Austria
EU contribution
€ 215 137,91
Address
Christoph Probst Platz 1
6020 Innsbruck
Activity type
Higher or Secondary Education Establishments
PD-VALUE BV
Netherlands
EU contribution
€ 102 711,25
Address
Molenaarserf 102
3991 KT Houten
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)